Install
Research shows gut microbiome could delay onset of type 1 diabetes Race opens first Australian clinical site for RC220 Phase 1 solid tumour trial Biome secures news debt facility to support growth Algorae announces the appointment of chief commercial officer Percheron updates shareholders after disappointing clinical t
- 30articles · 30d
- 13+ hour agolatest article
- Aug 17, 2026earliest in window
- 97%with images
- 336avg words
- Medical 23
- Health & Wellness 20
- Health 13
- Economy, Business & Finance 11
- Business & Industrial 6
- Science & Technology 5
- Finance & Business 4
- News 4
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Professor Fiona Wood to give Depaz Oration at AusBiotech International Conference
3+ week, 4+ day ago (252+ words) dedicated to driving innovation and strategic growth to support the advancement of Australia’s life science...AusBiotech said it looks forward to welcoming Professor Wood and the broader life sciences community...
Australian biotech Immuron takes gut health treatment to the US market
1+ week, 16+ hour ago (359+ words) product PROIBS to American shelves after striking an exclusive distribution deal with Swedish life science...He said the deal allows Immuron to offer customers a proven premium product backed by science and recommended...
Cartherics pursues new cell therapy route for cancer and endometriosis
1+ week, 6+ day ago (421+ words) “The purpose of Dr Metelli’s and my science is to learn how to safely kill cancer cells that sustain...
Neurizon Therapeutics appoints Chris Bremer as chief executive to steer ALS drug through final trial stage
1+ week, 16+ hour ago (504+ words) BiotechDispatch Neurizon Therapeutics appoints Chris Bremer as chief executive to steer ALS drug through final trial stage Neurizon Therapeutics, the Melbourne-based biotechnology company developing a treatment for the fatal neurological disease ALS, has appointed Dr Chris Bremer as its new…...